Cause of Androgenic Alopecia

Ustuner, Emin Tuncay

doi:10.1097/gox.0000000000000005

Cited by 30 publications

(22 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New hair cycle begins when these HFSCs divide normally, however, due to their inactivation in AGA, vellus hair are produced instead of a terminal hair . Apart from loss of stem cells, testosterone also plays an important role in the miniaturization of hair follicles …”

Section: Introductionmentioning

confidence: 99%

Stromal vascular fraction‐enriched platelet‐rich plasma therapy reverses the effects of androgenetic alopecia

Butt

Hussain

Ahmad

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Since antiquity, humans have been trying to devise remedies to cure androgenetic alopecia (AGA). These efforts include use of oral and topical concoctions and hair transplant strategies. As AGA affects people of all colors and creed, there has been a continuous effort to find a magic bullet against AGA. Unfortunately, to date, all the strategies to negate AGA effects have limitations and thus require new treatment options. Aim To evaluate the efficacy of use of stromal vascular fraction (SVF) in androgenetic alopecia patients. Methods Stromal vascular fraction was obtained by enzymatic digestion of autologous adipose tissue. The patients were divided into two groups, that is, platelet‐rich plasma (PRP) group and SVF‐PRP group. In PRP group, only PRP was injected, while in SVF‐PRP group a mixture of PRP and SVF was injected in affected scalp areas. After two sessions (4 weeks apart), the patients in both groups were assessed and analyzed using various parameters. Results Mean hair density in PRP group was increased from 52.44 hair/cm2 to 63.72 hair/cm2 (21.51% increase); while in SVF‐PRP group, it was 37.66 hair/cm2 before treatment and 57.11 hair/cm2 after SVF‐PRP therapy (51.64% increase). Percentage reduction in pull test was more significant in SVF‐PRP group (80.78 ± 5.84) as compared to PRP group (34.01 ± 22.44). The physician and patient assessment scores also indicated a significant improvement in SVF‐PRP group. Conclusion A combined SVF‐PRP therapy reversed effects of AGA more efficiently as compared to PRP therapy alone.

show abstract

Section: Introductionmentioning

confidence: 99%

Stromal vascular fraction‐enriched platelet‐rich plasma therapy reverses the effects of androgenetic alopecia

Butt

Hussain

Ahmad

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…DHT's presence is what causes the genes to express the balding gene and the blood levels alone do not relate directly to the extent of hair loss. Thus we say, not a raised DHT but a higher sensitivity of the hair roots is responsible for hair loss [11,[29][30][31] . Studies by Sawaya and Price [32] , on the 5-alpha reductase type 1, type 2, aromatase and androgen receptors, along with the cutaneous androgen metabolism studies by Chen et al [33] and Hoffman and Happle [34] current understanding of androgenic alopecia, all support the conclusion that sensitivity of the follicles is of greater concern than raised levels of androgens.…”

Section: Introductionmentioning

confidence: 99%

Controlled clinical trial for evaluation of hair growth with low dose cyclical nutrition therapy in men and women without the use of finasteride

Rajput¹

2017

PAR

View full text Add to dashboard Cite

“…It has also been shown that gender is a prognostic factor, with approximately 60-70% of deaths being in men [5,6], suggesting that steroid hormones may be a contributing factor to the severity of the disease. In further support of this, recent studies have shown that men with male pattern hair loss (caused by elevated androgen signalling [7]), are at higher risk of suffering more severe COVID-19 symptoms [8,9].…”

Section: Introductionmentioning

confidence: 77%

TMPRSS2, required for SARS-CoV-2 entry, is downregulated in lung cells by enzalutamide, a prostate cancer therapeutic

Leach¹,

Isac²,

Bevan³

et al. 2020

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, attacks various organs but most destructively the lung. It has been shown that SARS-CoV-2 entry into lung cells requires two host cell surface proteins: ACE2 and TMPRSS2. Downregulation of one or both of these is thus a potential therapeutic approach for COVID-19. TMPRSS2 is a known target of the androgen receptor, a ligand-activated transcription factor; activation of the androgen receptor increases TMPRSS2 levels in various tissues, most notably the prostate. We show here that treatment with the antiandrogen enzalutamide – a well-tolerated drug widely used in advanced prostate cancer – reduces TMPRSS2 levels in human lung cells. Further, enzalutamide treatment of mice dramatically decreased Tmprss2 levels in the lung. In support of this new experimental data, analysis of existing datasets shows striking co- expression of AR and TMPRSS2, including in specific lung cell types that are targeted by SARS- CoV-2. Together, the data presented provides strong evidence to support clinical trials to assess the efficacy of antiandrogens as a treatment option for COVID-19.

show abstract

Cause of Androgenic Alopecia

Cited by 30 publications

References 31 publications

Stromal vascular fraction‐enriched platelet‐rich plasma therapy reverses the effects of androgenetic alopecia

Stromal vascular fraction‐enriched platelet‐rich plasma therapy reverses the effects of androgenetic alopecia

Controlled clinical trial for evaluation of hair growth with low dose cyclical nutrition therapy in men and women without the use of finasteride

TMPRSS2, required for SARS-CoV-2 entry, is downregulated in lung cells by enzalutamide, a prostate cancer therapeutic

Contact Info

Product

Resources

About